Reference Product Sample Abuses: Indian Firms Flag Concerns With FTC
Executive Summary
Indian generic firms appear to be weighing in on controversy around brand name company tactics in the US to block access to reference products for bioequivalence testing – but generic firms may ultimately need legislation to resolve their concerns.